skip to content
Detailed Quote
5i Report

Review of Knight Therapeutics

SEP 19, 2018 - Specialty Pharmaceutical company focused on later stage commercialization of drugs. The company continues to hold on to a high balance of cash, waiting for the right opportunity. Despite strong fundamentals and management, the increased opportunity cost and stock trading sideways justify the rating to be downgraded one notch to 'B+'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Analyst Recommendations
5i Recent Questions

Q: I know members have started to raise questions about Knight Therapeutics' cash balance and when they will use it to make a large acquisition.
I am reminded of this YouTube video from 2014:

Jonathan Goodman was quite clear when he made this speech that it could be 10-15 years before he investors could see big results.

My main questions are: realistically, how much pressure can shareholders place on the company? Is it possible that impatient shareholders could push GUD to make wrong move/acquisition with the cash?

Read Answer Asked by Mike on January 15, 2019
CMS Buy Now
Share Information
News and Media